Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2006;333:754 (7 October), doi:10.1136/bmj.333.7571.754
| The first 150 words of the full text of this article appear below. |
EDITORIn their support for making naloxone freely available, Strang et al state that naloxone saves lives,1 yet it can also be dangerous, even lethal.2 Many other reports of adverse reactions are from use in health care, so more harm is likely in the hands of untrained people, especially as some may be intoxicated themselves when the drug is used. This needs to be carefully balanced by the likely benefits and other viable alternatives to address mortality from overdose, given finite budgets and workforce.
| |||||||||||
Why Strang et al dwell on the wording of existing local prohibitions is unclear. As with injecting centres, a community naloxone trial would require indemnifying legislation. A localised pilot study in a high risk town might use other towns as controls.
Apart from theoretical endorsement on pharmacological grounds, the only reference Strang et al give supporting community naloxone is an unpublished communication (D Bigg, Chicago).
Andrew Byrne, dependency physician
75 Redfern Street, Redfern, NSW 2016, Australia ajbyrne@ozemail.com.au